
ANCA-associated vasculitis (AAV) remains challenging despite improved outcomes with immunosuppressants like rituximab. New therapies such as avacopan offer better efficacy and reduced toxicity. Emerging treatments, including CAR-T cells and complement inhibitors, are under investigation. Lower glucocorticoid dosing and biomarker-driven studies mark a shift toward safer, more personalized AAV care.
Like
Save
Share